T-0156 hydrochloride

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 532801

CAS#: 324572-93-2 (HCl)

Description: T 0156 is a potent and selective inhibitor of phosphodiesterase type 5 (PDE5). It is more selective than sildenafil (IC50 values are 0.23, 56 and > 63000 nM for T 0156 and 3.6, 29 and > 270 nM for sildenafil at PDE5, PDE6 and PDEs 1 - 4 respectively). T 0156 is selective over 30 other enzymes and receptors (IC50 > 10 mM) and potentiates electrical field stimulation-induced relaxation of isolated rabbit corpus cavernosum. T-0156 would be a useful pharmacological tool as a potent and highly selective phosphodiesterase type 5 inhibitor.

Chemical Structure

img
T-0156 hydrochloride
CAS# 324572-93-2 (HCl)
Instruction

Theoretical Analysis

MedKoo Cat#: 532801
Name: T-0156 hydrochloride
CAS#: 324572-93-2 (HCl)
Chemical Formula: C31H30ClN5O7
Exact Mass: 0.00
Molecular Weight: 620.060
Elemental Analysis: C, 60.05; H, 4.88; Cl, 5.72; N, 11.29; O, 18.06

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 324572-92-1 (free base)   324572-93-2 (HCl)    

Synonym: T 0156 hydrochloride, T 0156 HCl, T 0156, T-0156, T0156

IUPAC/Chemical Name: 1,2-Dihydro-2-[(2-methyl-4-pyridinyl)methyl]-1-oxo-8-(2-pyrimidinylmethoxy)-4-(3,4,5-trimethoxyphenyl)-2,7-naphthyridine-3-carboxylic acid methyl ester hydrochloride

InChi Key: RBJCBXAXUHCWBR-UHFFFAOYSA-N

InChi Code: InChI=1S/C31H29N5O7.ClH/c1-18-13-19(7-11-32-18)16-36-27(31(38)42-5)25(20-14-22(39-2)28(41-4)23(15-20)40-3)21-8-12-35-29(26(21)30(36)37)43-17-24-33-9-6-10-34-24;/h6-15H,16-17H2,1-5H3;1H

SMILES Code: O=C(C1=C(C2=CC(OC)=C(OC)C(OC)=C2)C3=CC=NC(OCC4=NC=CC=N4)=C3C(N1CC5=CC(C)=NC=C5)=O)OC.[H]Cl

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 620.06 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Santos AI, Carreira BP, Nobre RJ, Carvalho CM, Araújo IM. Stimulation of neural stem cell proliferation by inhibition of phosphodiesterase 5. Stem Cells Int. 2014;2014:878397. doi: 10.1155/2014/878397. Epub 2014 Jan 12. PubMed PMID: 24550991; PubMed Central PMCID: PMC3914480.

2: Parlak A, Yildirim S, Bagcivan I, Durmus N. Role of new agents affecting NO/cGMP pathway on ovalbumin-sensitized guinea pig trachea. Exp Lung Res. 2012 Oct;38(8):420-6. doi: 10.3109/01902148.2012.719281. PubMed PMID: 23030645.

3: Al-Zobaidy MJ, Craig J, Brown K, Pettifor G, Martin W. Stimulus-specific blockade of nitric oxide-mediated dilatation by asymmetric dimethylarginine (ADMA) and monomethylarginine (L-NMMA) in rat aorta and carotid artery. Eur J Pharmacol. 2011 Dec 30;673(1-3):78-84. doi: 10.1016/j.ejphar.2011.10.024. Epub 2011 Oct 26. PubMed PMID: 22056836.

4: Goto M, Ikeyama K, Tsutsumi M, Denda S, Denda M. Phosphodiesterase inhibitors block the acceleration of skin permeability barrier repair by red light. Exp Dermatol. 2011 Jul;20(7):568-71. doi: 10.1111/j.1600-0625.2011.01255.x. Epub 2011 Mar 16. PubMed PMID: 21410772.

5: Zhang Y, Quock LP, Chung E, Ohgami Y, Quock RM. Involvement of a NO-cyclic GMP-PKG signaling pathway in nitrous oxide-induced antinociception in mice. Eur J Pharmacol. 2011 Mar 11;654(3):249-53. doi: 10.1016/j.ejphar.2011.01.006. Epub 2011 Jan 14. PubMed PMID: 21238450; PubMed Central PMCID: PMC3050811.

6: Liu CQ, Wong SL, Leung FP, Tian XY, Lau CW, Lu L, Yao X, Chen ZY, Yao T, Huang Y. Prostanoid TP receptor-mediated impairment of cyclic AMP-dependent vasorelaxation is reversed by phosphodiesterase inhibitors. Eur J Pharmacol. 2010 Apr 25;632(1-3):45-51. doi: 10.1016/j.ejphar.2010.01.008. Epub 2010 Jan 21. PubMed PMID: 20096281.

7: Liu CQ, Leung FP, Lee VW, Lau CW, Yao X, Lu L, Huang Y. Prevention of nitroglycerin tolerance in vitro by T0156, a selective phosphodiesterase type 5 inhibitor. Eur J Pharmacol. 2008 Aug 20;590(1-3):250-4. doi: 10.1016/j.ejphar.2008.05.009. Epub 2008 May 20. PubMed PMID: 18554583.

8: Santos-Silva AJ, Cairrão E, Morgado M, Alvarez E, Verde I. PDE4 and PDE5 regulate cyclic nucleotides relaxing effects in human umbilical arteries. Eur J Pharmacol. 2008 Mar 17;582(1-3):102-9. doi: 10.1016/j.ejphar.2007.12.017. Epub 2007 Dec 28. PubMed PMID: 18234184.

9: Mochida H, Noto T, Inoue H, Yano K, Kikkawa K. T-0156, a novel phosphodiesterase type 5 inhibitor, and sildenafil have different pharmacological effects on penile tumescence and electroretinogram in dogs. Eur J Pharmacol. 2004 Feb 6;485(1-3):283-8. PubMed PMID: 14757152.

10: Mochida H, Takagi M, Inoue H, Noto T, Yano K, Fujishige K, Sasaki T, Yuasa K, Kotera J, Omori K, Kikkawa K. Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor. Eur J Pharmacol. 2002 Dec 5;456(1-3):91-8. PubMed PMID: 12450574.